Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Acetamides
/ pharmacology
Alzheimer Disease
/ chemically induced
Animals
Antidepressive Agents
/ pharmacology
Anxiety
/ metabolism
Behavior, Animal
/ drug effects
Disease Models, Animal
Exploratory Behavior
/ drug effects
Hippocampus
/ drug effects
Male
Maze Learning
/ drug effects
Melatonin
/ metabolism
Memory Disorders
/ chemically induced
Rats
Rats, Sprague-Dawley
Streptozocin
Agomelatine
Alzheimer's disease
Behavior
Beta amyloid
Cell loss
Inflammation
Journal
Hormones and behavior
ISSN: 1095-6867
Titre abrégé: Horm Behav
Pays: United States
ID NLM: 0217764
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
17
04
2018
revised:
09
11
2018
accepted:
15
11
2018
pubmed:
20
11
2018
medline:
23
1
2020
entrez:
20
11
2018
Statut:
ppublish
Résumé
Experimental findings suggest that the melatonin system has a beneficial role in models of Alzheimer's disease (ADs). The aim of the present study was to explore whether the atypical antidepressant agomelatine (Ago), which is a melatonin MT
Identifiants
pubmed: 30452900
pii: S0018-506X(18)30168-5
doi: 10.1016/j.yhbeh.2018.11.007
pii:
doi:
Substances chimiques
Acetamides
0
Antidepressive Agents
0
agomelatine
137R1N49AD
Streptozocin
5W494URQ81
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-19Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.